Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's disease (PD)

被引：0
|
作者：
Espay, A.
Pahwa, R.
Ellenbogen, A.
Stocchi, F.
Giladi, N.
Salin, L.
Sasson, N.
Pereira, J.
Rascol, O.
机构：
来源：
MOVEMENT DISORDERS | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
653
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 50 条
  • [21] ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Adar, L.
    Minei, T. Rachmilewitz
    Oren, S.
    MOVEMENT DISORDERS, 2017, 32
  • [22] Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD
    Olanow, W.
    Ellenbogen, A.
    Djaldetti, R.
    Minei, T. Rachmilewitz
    Cohen, Y.
    Oren, S.
    Kieburtz, K.
    MOVEMENT DISORDERS, 2017, 32
  • [23] A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease
    Rosebraugh, Matthew
    Kym, Philip
    Liu, Wei
    Facheris, Maurizio
    Benesh, Janet
    NEUROLOGY, 2019, 92 (15)
  • [24] Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease
    Busk, Karin
    Nyholm, Dag
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (08) : 1000 - 1001
  • [25] Pharmacokinetics of levodopa/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson's disease
    Rosebraugh, M.
    Kym, P.
    Liu, W.
    Facheris, M.
    Benesh, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 838 - 838
  • [26] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612 FOR PARKINSON'S DISEASE: THREE-YEAR DATA FROM THE OPEN-LABEL BEYOND STUDY
    Stocchi, F.
    Poewe, W.
    Ellenbogen, A.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [27] ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses
    Giladi, Nir
    Caraco, Yoseph
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Cohen, Yael
    Minei, Tamar Rachmilewitz
    Oren, Sheila
    NEUROLOGY, 2017, 88
  • [28] The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson's disease
    Poewe, W.
    Stocchi, F.
    Espay, A.
    Minei, T. Rachmilewitz
    Oren, S.
    Case, R.
    Kieburtz, K.
    Olanow, C.
    MOVEMENT DISORDERS, 2018, 33 : S131 - S132
  • [29] 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease
    Ricciardi, Lucia
    Bove, Francesco
    Espay, Kristy J.
    Lena, Francesco
    Modugno, Nicola
    Poon, Yu-Yan
    Krikorian, Robert
    Espay, Alberto J.
    Fasano, Alfonso
    MOVEMENT DISORDERS, 2016, 31 (04) : 597 - 598
  • [30] Pharmacokinetic profile of ND0612L (levodopa/carbidopa for subcutaneous infusion) in patients with moderate to severe Parkinson's disease
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Cohen, Y.
    Yacobi-Zeevi, O.
    Oren, S.
    MOVEMENT DISORDERS, 2015, 30 : S87 - S88
12345